Status:
COMPLETED
This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Fibromyalgia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081100 and who wish to receive open-label pregabal...
Eligibility Criteria
Inclusion
- Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol A0081100, and must have received pregabalin/placebo under double-blind conditions.
Exclusion
- Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia Study A0081100 which was determined to be related to the study medication by the investigator or the sponsor.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
357 Patients enrolled
Trial Details
Trial ID
NCT00346034
Start Date
December 1 2006
End Date
February 1 2008
Last Update
January 22 2021
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kelowna, British Columbia, Canada, V1Y 2H4
2
Pfizer Investigational Site
Winnipeg, Manitoba, Canada, R3A 1R9
3
Pfizer Investigational Site
Bathurst, New Brunswick, Canada, E2A 4X7
4
Pfizer Investigational Site
St. John's, Newfoundland and Labrador, Canada, A1B 3E1